About Freenome AI
Freenome is a precision medicine company pioneering early cancer detection through blood-based screening tests. The company combines multiomics technology with artificial intelligence to detect cancer in its earliest, most treatable stages using a standard blood draw. Freenome's intelligent screening platform analyzes genomic, epigenomic, and proteomic biomarkers to detect cancer-specific signals in the bloodstream, including tumor-derived cell-free DNA (cfDNA). The company's first commercial focus is colorectal cancer (CRC) screening, addressing a critical need as CRC is the world's second deadliest cancer with over 50,000 deaths annually in the U.S. alone. Freenome's PREEMPT CRC Study, the largest clinical validation study for a blood-based CRC screening test, enrolled over 40,000 participants across more than 200 study sites and published landmark results in JAMA demonstrating clinical accuracy. The company is expanding its research into lung cancer screening through the PROACT LUNG Study and multiple cancer types through the Vallania Study. Freenome's Clinical Laboratory is CLIA-certified to perform high complexity clinical testing. The company aims to provide a less invasive, more accessible screening option to overcome barriers like discomfort and preparation that lead to low adherence rates in traditional screening methods.
Clinical Focus
Medical conditions and clinical areas addressed by Freenome AI.
Who It Serves
Milestones & Awards
Recent Milestones
JAMA publication of PREEMPT CRC Study results (2025), largest clinical validation study for blood-based CRC screening with 40,000+ participants. Completion of Vallania Study recruitment. Ongoing enrollment in PROACT LUNG Study.
Social & Media
Company Details
- Headquarters
- Brisbane, CA, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.